Evercore ISI Has Lowered Expectations for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its target price dropped by analysts at Evercore ISI from $130.00 to $128.00 in a report released on Thursday,Benzinga reports. The firm presently has an “in-line” rating on the medical research company’s stock. Evercore ISI’s target price would suggest a potential upside of 1.88% from the company’s current price.

A number of other equities analysts have also recently issued reports on A. UBS Group cut their price target on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a report on Thursday, May 29th. Robert W. Baird cut their price target on Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating on the stock in a report on Thursday, May 22nd. Barclays increased their price target on Agilent Technologies from $115.00 to $125.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 24th. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Saturday, June 28th. Finally, JPMorgan Chase & Co. cut their target price on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 29th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and a consensus price target of $139.25.

Agilent Technologies Stock Performance

NYSE:A opened at $125.63 on Thursday. The company has a market capitalization of $35.69 billion, a PE ratio of 29.49, a P/E/G ratio of 3.80 and a beta of 1.22. The company has a 50 day simple moving average of $118.39 and a two-hundred day simple moving average of $116.65. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.60 and a current ratio of 2.25. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $153.84.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Research analysts anticipate that Agilent Technologies will post 5.58 earnings per share for the current year.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Investors Weigh In On Agilent Technologies

Large investors have recently bought and sold shares of the business. Brighton Jones LLC boosted its position in Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after purchasing an additional 270 shares during the last quarter. Integrated Wealth Concepts LLC boosted its position in Agilent Technologies by 24.5% in the fourth quarter. Integrated Wealth Concepts LLC now owns 3,413 shares of the medical research company’s stock worth $458,000 after purchasing an additional 671 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new position in Agilent Technologies in the fourth quarter worth about $699,000. AQR Capital Management LLC boosted its position in Agilent Technologies by 38.6% in the fourth quarter. AQR Capital Management LLC now owns 433,313 shares of the medical research company’s stock worth $58,211,000 after purchasing an additional 120,725 shares during the last quarter. Finally, Guardian Capital LP boosted its position in Agilent Technologies by 7.8% in the fourth quarter. Guardian Capital LP now owns 6,235 shares of the medical research company’s stock worth $838,000 after purchasing an additional 453 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.